A5061198575- Diabetes Treatment and Management
- Diabetes Management and Research
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Metabolism, Diabetes, and Cancer
- Diabetes and associated disorders
- Cardiovascular Function and Risk Factors
- Diet and metabolism studies
- Pancreatic function and diabetes
- Bariatric Surgery and Outcomes
- Blood Pressure and Hypertension Studies
- Liver Disease Diagnosis and Treatment
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Diabetes Management and Education
- Chronic Disease Management Strategies
- Health Systems, Economic Evaluations, Quality of Life
- Nutritional Studies and Diet
- Adipokines, Inflammation, and Metabolic Diseases
- Peripheral Artery Disease Management
- Psoriasis: Treatment and Pathogenesis
- Diet, Metabolism, and Disease
- Lipoproteins and Cardiovascular Health
- Cerebrovascular and Carotid Artery Diseases
- Medication Adherence and Compliance
- Obesity and Health Practices
- Potassium and Related Disorders
Sahlgrenska University Hospital
2016-2025
University of Gothenburg
2016-2025
Centre of Registers Vastra Gotaland
2016-2025
Region Västra Götaland
2017-2024
Statens Serum Institut
2022
University of Glasgow
2017-2022
Swedish Academy
2022
British Heart Foundation
2022
University Medical Center Utrecht
2022
Sint Franciscus Gasthuis
2022
Patients with diabetes are at higher risk for death and cardiovascular outcomes than the general population. We investigated whether excess of events among patients type 2 could be reduced or eliminated.
Long-term trends in excess risk of death and cardiovascular outcomes have not been extensively studied persons with type 1 diabetes or 2 diabetes.We included patients registered the Swedish National Diabetes Register from 1998 through 2012 followed them 2014. Trends deaths events were estimated Cox regression standardized incidence rates. For each patient, controls who matched for age, sex, county randomly selected general population.Among diabetes, absolute changes during study period rates...
The ESC Guidelines represent the views of and were produced after careful consideration scientific medical knowledge evidence available at time their publication.The is not responsible in event any contradiction, discrepancy, and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies.Health professionals are encouraged take fully into account when exercising clinical...
Background: Risk of cardiovascular disease (CVD) and mortality for patients with versus without type 2 diabetes mellitus (T2DM) appears to vary by the age at T2DM diagnosis, but few population studies have analyzed CVD outcomes associations across full range. Methods: With use Swedish National Diabetes Registry, everyone registered in Registry between 1998 2012 was included. Controls were randomly selected from general matched age, sex, county. The analysis cohort comprised 318 083 just...
OBJECTIVE Traditional blood glucose–lowering agents do not sustain adequate glycemic control in most type 2 diabetic patients. Preclinical studies with exenatide have suggested sustained improvements β-cell function. We investigated the effects of 52 weeks treatment or insulin glargine followed by an off-drug period on hyperglycemic clamp–derived measures function, control, and body weight. RESEARCH DESIGN AND METHODS Sixty-nine metformin-treated patients diabetes were randomly assigned to...
Abstract Objective To assess the association between use of sodium glucose cotransporter 2 (SGLT2) inhibitors and seven serious adverse events current concern. Design Register based cohort study. Setting Sweden Denmark from July 2013 to December 2016. Participants A propensity score matched 17 213 new users SGLT2 (dapagliflozin, 61%; empagliflozin, 38%; canagliflozin, 1%) active comparator, glucagon-like peptide 1 (GLP1) receptor agonists. Main outcome measures The primary outcomes were...
OBJECTIVE We previously showed that exenatide (EXE) enhanced insulin secretion after 1 year of treatment, relative to glargine (GLAR), with a similar glucose-lowering action. These effects were not sustained 4-week off-drug period. This article reports the results additional 2 years exposure. RESEARCH DESIGN AND METHODS Sixty-nine metformin-treated patients type diabetes randomized EXE or GLAR. Forty-six entered 2-year extension study in which they continued their allocated therapy....
<b>Objective</b> To investigate the long term effects of continuous subcutaneous insulin infusion (insulin pump therapy) on cardiovascular diseases and mortality in people with type 1 diabetes. <b>Design </b>Observational study. <b>Setting </b>Swedish National Diabetes Register, Sweden 2005-12. <b>Participants</b> 18 168 diabetes, 2441 using therapy 15 727 multiple daily injections. <b>Main outcome measures</b> Cox regression analysis was used to estimate hazard ratios for outcomes,...
Abstract Aims To develop and validate a recalibrated prediction model (SCORE2-Diabetes) to estimate the 10-year risk of cardiovascular disease (CVD) in individuals with type 2 diabetes Europe. Methods results SCORE2-Diabetes was developed by extending SCORE2 algorithms using individual-participant data from four large-scale datasets comprising 229 460 participants (43 706 CVD events) without previous CVD. Sex-specific competing risk-adjusted models were used including conventional factors...
Whether infection with SARS-CoV-2 leads to excess risk of requiring hospitalization or intensive care in persons diabetes has not been reported, nor have factors associated increased for these outcomes.
The goal of this work was to investigate trends (2001-2019) for cardiovascular events and cardiometabolic risk factor levels in individuals with type 2 diabetes (T2D) matched control subjects.This study included 679 072 T2D from the Swedish National Diabetes Register 643 800 subjects. Incident outcomes comprised coronary artery disease, acute myocardial infarction, cerebrovascular heart failure (HF). Trends time first event each outcome were analyzed Cox regression standardized incidence...
Abstract Objective To investigate whether use of glucagon-like peptide 1 (GLP1) receptor agonists is associated with increased risk thyroid cancer. Design Scandinavian cohort study. Setting Denmark, Norway, and Sweden, 2007-21. Participants Patients who started GLP1 agonist treatment were compared patients dipeptidyl peptidase 4 (DPP4) inhibitor treatment, in an additional analysis, sodium-glucose cotransporter 2 (SGLT2) treatment. Main outcome measures Thyroid cancer identified from...
To monitor glycemic control, treatable risk factors, and treatment profile for quality assessment of diabetes care on a national scale.Four samples 23,546, 32,903, 30,311, 29,769 patients with (1996-1999) were studied based repeated screening by the National Diabetes Register, Sweden, participation both hospitals primary health care. Clinical characteristics included age, sex, duration treatment, control (HbA(1c)), office blood pressure (BP), BMI, smoking habits, use lipid-lowering drugs in...
To evaluate the effectiveness and safety of metformin use in clinical practice a large sample pharmacologically treated patients with type 2 diabetes different levels renal function.Observational study between July 2004 December 2010, mean follow-up 3.9 years.Hospital outpatient clinics primary care Sweden.51 675 men women diabetes, registered Swedish National Diabetes Register, on continuous glucose-lowering treatment oral hypoglycaemic agents (OHAs) or insulin.Risks cardiovascular disease...
The relationship between smoking habits, insulin resistance, and related risk factors for cardiovascular disease was examined in 57 middle-aged male smokers whose degree of resistance quantified by using the euglycemic clamp technique. Smoking habits correlated with consequently various manifestations syndrome including levels insulin, high-density lipoprotein cholesterol, triglycerides, plasminogen activator inhibitor-1 (PAI-1) activity. independent were also to total cholesterol...
Abstract. Eeg‐Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson A‐M, Gudbjörnsdóttir S, Eliasson B (Institute of Medicine, Sahlgrenska University Hospital, Gothenburg, Gothenburg; Department Public Health and Caring Sciences/Family Medicine Clinical Epidemiology, Uppsala University, Uppsala; Sciences, Lund Malmö; Sciences/Geriatrics, Center Registers in Region Västra Götaland, Sweden) New aspects HbA1c as a risk factor for cardiovascular diseases type 2 diabetes: an observational...
OBJECTIVE—Risk prediction models obtained in samples from the general population do not perform well type 2 diabetic patients. Recently, 5-year risk estimates were proposed as being more accurate than 10-year estimates. This study presents a diabetes-specific equation for estimation of absolute first incident fatal/nonfatal cardiovascular disease (CVD) patients with use A1C and clinical characteristics. RESEARCH DESIGN AND METHODS—The was based on 11,646 female male patients, aged 18–70...